Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Trimmed by Fiera Capital Corp

Fiera Capital Corp lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 350,329 shares of the biotechnology company’s stock after selling 9,667 shares during the period. Fiera Capital Corp’s holdings in Sarepta Therapeutics were worth $42,597,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. CIBC Asset Management Inc raised its position in shares of Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. Louisiana State Employees Retirement System raised its holdings in Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after buying an additional 100 shares during the period. UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 138 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after buying an additional 145 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in shares of Sarepta Therapeutics by 16.9% in the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SRPT has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday. They issued a “hold” rating and a $136.00 price target for the company. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 price target on the stock. Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Trading Up 0.1 %

Shares of SRPT stock opened at $109.81 on Thursday. The business’s 50 day moving average is $120.16 and its two-hundred day moving average is $125.22. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12 month low of $102.15 and a 12 month high of $173.25. The company has a market cap of $10.49 billion, a PE ratio of 87.85 and a beta of 0.75.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.